Strasbourg, France –November 14^th, 2017

Emosis, a medical device company specializing in cell-based hemostasis and thrombosis diagnostics, is glad to announce that the company has recently obtained its ISO 9001:2015 and ISO 13485:2016 certificates.

Download

Strasbourg, France – July, 2017

The ISTH Congress in Berlin (July 8^th – 13^th) has been a formidable scene for worldwide key opinion leaders and young promising researchers from the Hemostatis & Thrombosis world to lecture on the latest developments in research and innovation. Thrombosis and Hemostasis have been studied and presented in correlation with various topics, from Oncology to Pediatrics, through Women Health; overall this congress enriched Emosis team’s educational background.

Download

Strasbourg, France – July, 2017

Heparin-Induced thrombocytopenia and thrombosis (HIT/T) is an immune-mediated adverse reaction that occurs in patients who received heparin treatment. It is a severe condition that might be complicated by blood clot formation in about half of the patients. These blood clots most may be formed in the brain, the heart, the lungs, the gut and the limbs, leading to the stopping of blood supply, and thus to severe damage in affected organs. Consequently, quick, accurate and reliable diagnosing of HIT is essential for clinical decision and patient management.

Download

Strasbourg, France – June, 2017

Emosis, a medical device company specializing in cell-based hemostasis diagnostics, is proud to announce that Dr. Jean Amiral joins the Company as Chief Technology Officer (CTO), within a consultancy agreement with SH-Consulting.

Download

Strasbourg, France and Jerusalem, Israel, June 6th, 2017

The French diagnostic company Emosis SAS and the Israeli firm LeukoDx Ltd signed a cooperation agreement to set-up and validate an assay cartridge for real time in-vitro diagnostic (IVD) of blood coagulation. The project, which will be completed within 2 years, represents a total budget of 1.5 million euros and will be partially subsidised by the Eurostars grant.

Download

Strasbourg, France and Tel-Aviv, Israel March 2017

Emosis SAS, gladly announces that Aurore Andre has joined the company in order to head the newly founded Israeli subsidiary Emosis Ltd. At this stage, Aurore will primarily set-up Emosis Ltd.

Download

Strasbourg, France and Tel-Aviv, Israel March 2017

Emosis SAS, is opening a subsidiary in Israel. This new business entity, Emosis Ltd, headquartered in Tel Aviv, will be mostly dedicated to research and development of novel assays complementing the mother company existing technology platform and test portfolio. Emosis Ltd will also, when relevant, locally support commercialization and sales development of Emosis kits.

Download

Tel-Aviv and Haifa, Israel March 2017

The diagnostics company Emosis Ltd., BioRap Technologies and Rambam MedTech Ltd, the technology transfer companies of the Rappaport Institute at the Technion - Israel Institute of Technology and Rambam Healthcare Campus, have entered into an exclusive license agreement to develop and commercialize hypercoagulation kit for several indications based on microparticles.

Download

Strasbourg, France, March 2017

Download

Strasbourg, France, March 2016

Download